Article

Key clinical point: Female patients with meningioma have approximately 10-fold higher odds of developing breast cancer (BC) and should be screened more often for BC.

Major finding: Compared with the general population, the prevalence of BC was considerably higher in female patients with meningioma (odds ratio 9.87; 95% CI 7.31-13.32).

Study details: Findings are from a meta-analysis of 18 studies including patients diagnosed with intracranial or spinal meningioma or BC or both.

Disclosures: This study did not report the source of funding. The authors declared no conflicts of interest.

Source: Degeneffe A et al. The association between meningioma and breast cancer: A systematic review and meta-analysis. JAMA Netw Open. 2023;6(6):e2318620 (Jun 16). Doi: 10.1001/jamanetworkopen.2023.18620

Key clinical point: Female patients with meningioma have approximately 10-fold higher odds of developing breast cancer (BC) and should be screened more often for BC.

Major finding: Compared with the general population, the prevalence of BC was considerably higher in female patients with meningioma (odds ratio 9.87; 95% CI 7.31-13.32).

Study details: Findings are from a meta-analysis of 18 studies including patients diagnosed with intracranial or spinal meningioma or BC or both.

Disclosures: This study did not report the source of funding. The authors declared no conflicts of interest.

Source: Degeneffe A et al. The association between meningioma and breast cancer: A systematic review and meta-analysis. JAMA Netw Open. 2023;6(6):e2318620 (Jun 16). Doi: 10.1001/jamanetworkopen.2023.18620

Key clinical point: Female patients with meningioma have approximately 10-fold higher odds of developing breast cancer (BC) and should be screened more often for BC.

Major finding: Compared with the general population, the prevalence of BC was considerably higher in female patients with meningioma (odds ratio 9.87; 95% CI 7.31-13.32).

Study details: Findings are from a meta-analysis of 18 studies including patients diagnosed with intracranial or spinal meningioma or BC or both.

Disclosures: This study did not report the source of funding. The authors declared no conflicts of interest.

Source: Degeneffe A et al. The association between meningioma and breast cancer: A systematic review and meta-analysis. JAMA Netw Open. 2023;6(6):e2318620 (Jun 16). Doi: 10.1001/jamanetworkopen.2023.18620

Key clinical point: Adherence to a Mediterranean diet before being diagnosed with breast cancer (BC) may improve survival outcomes, particularly in postmenopausal women.

Major finding: A low vs medium adherence to Mediterranean diet was associated with a 13% higher risk for all-cause mortality (hazard ratio [HR] 1.13;  95% CI 1.01-1.26). The risk for overall mortality reduced by 8% (HR 0.92;  95% CI 0.87-0.97) for every 3-unit increase in the adapted relative Mediterranean diet score, with the association sustaining in case of postmenopausal women only.

Study details: Findings are from an analysis including 13,270 women with incident BC from a prospective, multicenter European cohort of 318,686 women.

Disclosures: This study was funded by the AECC Scientific Foundation. The authors declared no conflicts of interest.

Source: Castro-Espin C et al. Association of Mediterranean diet with survival after breast cancer diagnosis in women from nine European countries: Results from the EPIC cohort study. BMC Med. 2023;21:225 (Jun 26). Doi: 10.1186/s12916-023-02934-3

Key clinical point: Adherence to a Mediterranean diet before being diagnosed with breast cancer (BC) may improve survival outcomes, particularly in postmenopausal women.

Major finding: A low vs medium adherence to Mediterranean diet was associated with a 13% higher risk for all-cause mortality (hazard ratio [HR] 1.13;  95% CI 1.01-1.26). The risk for overall mortality reduced by 8% (HR 0.92;  95% CI 0.87-0.97) for every 3-unit increase in the adapted relative Mediterranean diet score, with the association sustaining in case of postmenopausal women only.

Study details: Findings are from an analysis including 13,270 women with incident BC from a prospective, multicenter European cohort of 318,686 women.

Disclosures: This study was funded by the AECC Scientific Foundation. The authors declared no conflicts of interest.

Source: Castro-Espin C et al. Association of Mediterranean diet with survival after breast cancer diagnosis in women from nine European countries: Results from the EPIC cohort study. BMC Med. 2023;21:225 (Jun 26). Doi: 10.1186/s12916-023-02934-3

Key clinical point: Adherence to a Mediterranean diet before being diagnosed with breast cancer (BC) may improve survival outcomes, particularly in postmenopausal women.

Major finding: A low vs medium adherence to Mediterranean diet was associated with a 13% higher risk for all-cause mortality (hazard ratio [HR] 1.13;  95% CI 1.01-1.26). The risk for overall mortality reduced by 8% (HR 0.92;  95% CI 0.87-0.97) for every 3-unit increase in the adapted relative Mediterranean diet score, with the association sustaining in case of postmenopausal women only.

Study details: Findings are from an analysis including 13,270 women with incident BC from a prospective, multicenter European cohort of 318,686 women.

Disclosures: This study was funded by the AECC Scientific Foundation. The authors declared no conflicts of interest.

Source: Castro-Espin C et al. Association of Mediterranean diet with survival after breast cancer diagnosis in women from nine European countries: Results from the EPIC cohort study. BMC Med. 2023;21:225 (Jun 26). Doi: 10.1186/s12916-023-02934-3

Key clinical point: Findings from this real-world study supported the previous evidence for improved clinical outcomes on adding pertuzumab to trastuzumab plus neoadjuvant chemotherapy (TCT) in patients with human epidermal growth factor receptor 2-positive (HER2+) early-stage breast cancer (BC).

Major finding: The pathological complete response (odds ratio 1.74; P = .032) and 5-year event-free survival (hazard ratio, 2.22; P = .041) rates were significantly worsened in patients receiving TCT vs pertuzumab+TCT. The incidence of serious adverse events did not differ significantly between both groups.

Study details: Findings are from a retrospective, observational study including 271 patients with HER2+ stage II-III BC who received TCT with (n = 137) or without pertuzumab (n = 134).

Disclosures: This study did not declare the source of funding. The authors declared no conflicts of interest.

Source: Fabbri A et al. Pathologic response and survival after neoadjuvant chemotherapy with or without pertuzumab in patients with HER2-positive breast cancer: The Neopearl nationwide collaborative study. Front Oncol. 2023;13:1177681 (Jun 27). Doi: 10.3389/fonc.2023.1177681

Key clinical point: Findings from this real-world study supported the previous evidence for improved clinical outcomes on adding pertuzumab to trastuzumab plus neoadjuvant chemotherapy (TCT) in patients with human epidermal growth factor receptor 2-positive (HER2+) early-stage breast cancer (BC).

Major finding: The pathological complete response (odds ratio 1.74; P = .032) and 5-year event-free survival (hazard ratio, 2.22; P = .041) rates were significantly worsened in patients receiving TCT vs pertuzumab+TCT. The incidence of serious adverse events did not differ significantly between both groups.

Study details: Findings are from a retrospective, observational study including 271 patients with HER2+ stage II-III BC who received TCT with (n = 137) or without pertuzumab (n = 134).

Disclosures: This study did not declare the source of funding. The authors declared no conflicts of interest.

Source: Fabbri A et al. Pathologic response and survival after neoadjuvant chemotherapy with or without pertuzumab in patients with HER2-positive breast cancer: The Neopearl nationwide collaborative study. Front Oncol. 2023;13:1177681 (Jun 27). Doi: 10.3389/fonc.2023.1177681

Key clinical point: Findings from this real-world study supported the previous evidence for improved clinical outcomes on adding pertuzumab to trastuzumab plus neoadjuvant chemotherapy (TCT) in patients with human epidermal growth factor receptor 2-positive (HER2+) early-stage breast cancer (BC).

Major finding: The pathological complete response (odds ratio 1.74; P = .032) and 5-year event-free survival (hazard ratio, 2.22; P = .041) rates were significantly worsened in patients receiving TCT vs pertuzumab+TCT. The incidence of serious adverse events did not differ significantly between both groups.

Study details: Findings are from a retrospective, observational study including 271 patients with HER2+ stage II-III BC who received TCT with (n = 137) or without pertuzumab (n = 134).

Disclosures: This study did not declare the source of funding. The authors declared no conflicts of interest.

Source: Fabbri A et al. Pathologic response and survival after neoadjuvant chemotherapy with or without pertuzumab in patients with HER2-positive breast cancer: The Neopearl nationwide collaborative study. Front Oncol. 2023;13:1177681 (Jun 27). Doi: 10.3389/fonc.2023.1177681

Key clinical point: According to an analysis of two large prospective US-based cohorts, the consumption of olive oil was not associated with an increased risk for breast cancer (BC) among women.

Major finding: Compared with women who never or rarely consumed olive oil, those with the highest consumption of olive oil (>1/2 tablespoon/day or >7 g/day) did not report an increased risk of developing BC (hazard ratio 1.01;  95% CI 0.93-1.09).

Study details: Findings are from an analysis of two large prospective cohorts of women who were free of cancer at baseline, the Nurses’ Health Study (n = 71,330) and Nurses’ Health Study II (n = 93,295), of whom 9638 women developed invasive BC after 3,744,068 person-years of follow-up.

Disclosures: This study was supported by the US National Institutes of Health and other sources. The authors declared no conflicts of interest.

Source: Romanos-Nanclares A et al. Consumption of olive oil and risk of breast cancer in U.S. women: Results from the Nurses' Health Studies. Br J Cancer. 2023 (Jun 13). Doi: 10.1038/s41416-023-02306-x

Key clinical point: According to an analysis of two large prospective US-based cohorts, the consumption of olive oil was not associated with an increased risk for breast cancer (BC) among women.

Major finding: Compared with women who never or rarely consumed olive oil, those with the highest consumption of olive oil (>1/2 tablespoon/day or >7 g/day) did not report an increased risk of developing BC (hazard ratio 1.01;  95% CI 0.93-1.09).

Study details: Findings are from an analysis of two large prospective cohorts of women who were free of cancer at baseline, the Nurses’ Health Study (n = 71,330) and Nurses’ Health Study II (n = 93,295), of whom 9638 women developed invasive BC after 3,744,068 person-years of follow-up.

Disclosures: This study was supported by the US National Institutes of Health and other sources. The authors declared no conflicts of interest.

Source: Romanos-Nanclares A et al. Consumption of olive oil and risk of breast cancer in U.S. women: Results from the Nurses' Health Studies. Br J Cancer. 2023 (Jun 13). Doi: 10.1038/s41416-023-02306-x

Key clinical point: According to an analysis of two large prospective US-based cohorts, the consumption of olive oil was not associated with an increased risk for breast cancer (BC) among women.

Major finding: Compared with women who never or rarely consumed olive oil, those with the highest consumption of olive oil (>1/2 tablespoon/day or >7 g/day) did not report an increased risk of developing BC (hazard ratio 1.01;  95% CI 0.93-1.09).

Study details: Findings are from an analysis of two large prospective cohorts of women who were free of cancer at baseline, the Nurses’ Health Study (n = 71,330) and Nurses’ Health Study II (n = 93,295), of whom 9638 women developed invasive BC after 3,744,068 person-years of follow-up.

Disclosures: This study was supported by the US National Institutes of Health and other sources. The authors declared no conflicts of interest.

Source: Romanos-Nanclares A et al. Consumption of olive oil and risk of breast cancer in U.S. women: Results from the Nurses' Health Studies. Br J Cancer. 2023 (Jun 13). Doi: 10.1038/s41416-023-02306-x

Key clinical point: Breast-conserving therapy (BCT) vs mastectomy resulted in higher improvement in survival without increasing the risk for locoregional recurrence (LRR) in patients with breast cancer (BC), regardless of their clinical nodal status.

Major finding: BCT vs mastectomy improved overall survival (hazard ratio [HR] 1.37; P < .001, and HR 1.46; P < .001, respectively) and BC-specific survival (HR 1.32; P < .001, and HR 1.44; P = .008, respectively) without increasing the risk for LRR (P = .14 and P = .70, respectively) in patients with clinical node-negative and node-positive BC.

Study details: Findings are from an analysis including 13,914 women with T1-3N0-3 BC (clinically node-negative BC n = 12,537 and clinically node-positive BC n = 1,377) from a prospectively maintained database, the majority of whom received systemic therapy.

Disclosures: This study did not declare the source of funding. The authors did not report any conflicts of interest.

Source: Vasilyeva E et al. Breast-conserving therapy is associated with improved survival without an increased risk of locoregional recurrence compared with mastectomy in both clinically node-positive and node-negative breast cancer patients. Ann Surg Oncol. 2023 (Jun 26). Doi: 10.1245/s10434-023-13784-x

Key clinical point: Breast-conserving therapy (BCT) vs mastectomy resulted in higher improvement in survival without increasing the risk for locoregional recurrence (LRR) in patients with breast cancer (BC), regardless of their clinical nodal status.

Major finding: BCT vs mastectomy improved overall survival (hazard ratio [HR] 1.37; P < .001, and HR 1.46; P < .001, respectively) and BC-specific survival (HR 1.32; P < .001, and HR 1.44; P = .008, respectively) without increasing the risk for LRR (P = .14 and P = .70, respectively) in patients with clinical node-negative and node-positive BC.

Study details: Findings are from an analysis including 13,914 women with T1-3N0-3 BC (clinically node-negative BC n = 12,537 and clinically node-positive BC n = 1,377) from a prospectively maintained database, the majority of whom received systemic therapy.

Disclosures: This study did not declare the source of funding. The authors did not report any conflicts of interest.

Source: Vasilyeva E et al. Breast-conserving therapy is associated with improved survival without an increased risk of locoregional recurrence compared with mastectomy in both clinically node-positive and node-negative breast cancer patients. Ann Surg Oncol. 2023 (Jun 26). Doi: 10.1245/s10434-023-13784-x

Key clinical point: Breast-conserving therapy (BCT) vs mastectomy resulted in higher improvement in survival without increasing the risk for locoregional recurrence (LRR) in patients with breast cancer (BC), regardless of their clinical nodal status.

Major finding: BCT vs mastectomy improved overall survival (hazard ratio [HR] 1.37; P < .001, and HR 1.46; P < .001, respectively) and BC-specific survival (HR 1.32; P < .001, and HR 1.44; P = .008, respectively) without increasing the risk for LRR (P = .14 and P = .70, respectively) in patients with clinical node-negative and node-positive BC.

Study details: Findings are from an analysis including 13,914 women with T1-3N0-3 BC (clinically node-negative BC n = 12,537 and clinically node-positive BC n = 1,377) from a prospectively maintained database, the majority of whom received systemic therapy.

Disclosures: This study did not declare the source of funding. The authors did not report any conflicts of interest.

Source: Vasilyeva E et al. Breast-conserving therapy is associated with improved survival without an increased risk of locoregional recurrence compared with mastectomy in both clinically node-positive and node-negative breast cancer patients. Ann Surg Oncol. 2023 (Jun 26). Doi: 10.1245/s10434-023-13784-x

Key clinical point: A neoadjuvant chemotherapy regimen with three cycles of fluorouracil, epirubicin, and cyclophosphamide followed by three cycles of docetaxel (FEC3‑D3) had comparable survival outcomes as four cycles of adriamycin and cyclophosphamide followed by four cycles of docetaxel (AC4‑D4) in patients with stage II/III breast cancer (BC).

Major finding: In the FEC3-D3 vs AC4-D4 treatment group, the pathological complete response rate was 12.4% vs 14.3%, respectively, and the 3-year disease-free survival rate was comparable (75.8% vs 75.6%). Grade 3/4 neutropenia was the most common adverse event in both groups (~20%).

Study details: Findings are from the phase 3, Neo-shorter study including 248 patients with stage II/III BC who were randomly assigned to receive FEC3-D3 or AC4-D4.

Disclosures: This study was supported by Sanofi-Aventis. Two authors declared serving as consultants, founders, or advisors; owning stocks in; or receiving research funding from various sources, including Sanofi. Other authors declared no conflicts of interest.

Source: Hwang I et al. Randomized phase III trial of a neoadjuvant regimen of four cycles of adriamycin plus cyclophosphamide followed by four cycles of docetaxel (AC4-D4) versus a shorter treatment of three cycles of FEC followed by three cycles of docetaxel (FEC3-D3) in node-positive breast cancer (Neo-shorter; NCT02001506). Breast Cancer Res Treat. 2023 (Jun 26). Doi: 10.1007/s10549-023-06971-7

Key clinical point: A neoadjuvant chemotherapy regimen with three cycles of fluorouracil, epirubicin, and cyclophosphamide followed by three cycles of docetaxel (FEC3‑D3) had comparable survival outcomes as four cycles of adriamycin and cyclophosphamide followed by four cycles of docetaxel (AC4‑D4) in patients with stage II/III breast cancer (BC).

Major finding: In the FEC3-D3 vs AC4-D4 treatment group, the pathological complete response rate was 12.4% vs 14.3%, respectively, and the 3-year disease-free survival rate was comparable (75.8% vs 75.6%). Grade 3/4 neutropenia was the most common adverse event in both groups (~20%).

Study details: Findings are from the phase 3, Neo-shorter study including 248 patients with stage II/III BC who were randomly assigned to receive FEC3-D3 or AC4-D4.

Disclosures: This study was supported by Sanofi-Aventis. Two authors declared serving as consultants, founders, or advisors; owning stocks in; or receiving research funding from various sources, including Sanofi. Other authors declared no conflicts of interest.

Source: Hwang I et al. Randomized phase III trial of a neoadjuvant regimen of four cycles of adriamycin plus cyclophosphamide followed by four cycles of docetaxel (AC4-D4) versus a shorter treatment of three cycles of FEC followed by three cycles of docetaxel (FEC3-D3) in node-positive breast cancer (Neo-shorter; NCT02001506). Breast Cancer Res Treat. 2023 (Jun 26). Doi: 10.1007/s10549-023-06971-7

Key clinical point: A neoadjuvant chemotherapy regimen with three cycles of fluorouracil, epirubicin, and cyclophosphamide followed by three cycles of docetaxel (FEC3‑D3) had comparable survival outcomes as four cycles of adriamycin and cyclophosphamide followed by four cycles of docetaxel (AC4‑D4) in patients with stage II/III breast cancer (BC).

Major finding: In the FEC3-D3 vs AC4-D4 treatment group, the pathological complete response rate was 12.4% vs 14.3%, respectively, and the 3-year disease-free survival rate was comparable (75.8% vs 75.6%). Grade 3/4 neutropenia was the most common adverse event in both groups (~20%).

Study details: Findings are from the phase 3, Neo-shorter study including 248 patients with stage II/III BC who were randomly assigned to receive FEC3-D3 or AC4-D4.

Disclosures: This study was supported by Sanofi-Aventis. Two authors declared serving as consultants, founders, or advisors; owning stocks in; or receiving research funding from various sources, including Sanofi. Other authors declared no conflicts of interest.

Source: Hwang I et al. Randomized phase III trial of a neoadjuvant regimen of four cycles of adriamycin plus cyclophosphamide followed by four cycles of docetaxel (AC4-D4) versus a shorter treatment of three cycles of FEC followed by three cycles of docetaxel (FEC3-D3) in node-positive breast cancer (Neo-shorter; NCT02001506). Breast Cancer Res Treat. 2023 (Jun 26). Doi: 10.1007/s10549-023-06971-7

Key clinical point: Rates of locoregional recurrence after surgery were different for different molecular subtypes of breast cancer (BC).

Major finding: Compared with patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor-negative (ERBB2− aka HER2−) BC, those with HR−/ERBB2+ BC had approximately three times worse ipsilateral breast tumor recurrence (IBTR)-free survival (adjusted hazard ratio [aHR] 2.95;  95% CI 2.15-4.06), whereas patients with triple-negative BC had the worst regional recurrence-free survival (aHR 2.95;  95% CI 2.37-3.67) and contralateral BC-free survival (aHR 2.12;  95% CI 1.64-2.75). IBTR was lower in older patients with BC (P < .001).

Study details: Findings are from a retrospective cohort study including 16,462 women with BC who underwent surgery.

Disclosures: This study was funded by the Ministry of Health and Welfare, Republic of Korea. Some authors declared being members of a board of directors, stockholders of, or receiving grants from various sources.

Source: Cheun JH et al. Locoregional recurrence patterns in patients with different molecular subtypes of breast cancer. JAMA Surg. 2023 (Jun 21). Doi: 10.1001/jamasurg.2023.2150

Key clinical point: Rates of locoregional recurrence after surgery were different for different molecular subtypes of breast cancer (BC).

Major finding: Compared with patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor-negative (ERBB2− aka HER2−) BC, those with HR−/ERBB2+ BC had approximately three times worse ipsilateral breast tumor recurrence (IBTR)-free survival (adjusted hazard ratio [aHR] 2.95;  95% CI 2.15-4.06), whereas patients with triple-negative BC had the worst regional recurrence-free survival (aHR 2.95;  95% CI 2.37-3.67) and contralateral BC-free survival (aHR 2.12;  95% CI 1.64-2.75). IBTR was lower in older patients with BC (P < .001).

Study details: Findings are from a retrospective cohort study including 16,462 women with BC who underwent surgery.

Disclosures: This study was funded by the Ministry of Health and Welfare, Republic of Korea. Some authors declared being members of a board of directors, stockholders of, or receiving grants from various sources.

Source: Cheun JH et al. Locoregional recurrence patterns in patients with different molecular subtypes of breast cancer. JAMA Surg. 2023 (Jun 21). Doi: 10.1001/jamasurg.2023.2150

Key clinical point: Rates of locoregional recurrence after surgery were different for different molecular subtypes of breast cancer (BC).

Major finding: Compared with patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor-negative (ERBB2− aka HER2−) BC, those with HR−/ERBB2+ BC had approximately three times worse ipsilateral breast tumor recurrence (IBTR)-free survival (adjusted hazard ratio [aHR] 2.95;  95% CI 2.15-4.06), whereas patients with triple-negative BC had the worst regional recurrence-free survival (aHR 2.95;  95% CI 2.37-3.67) and contralateral BC-free survival (aHR 2.12;  95% CI 1.64-2.75). IBTR was lower in older patients with BC (P < .001).

Study details: Findings are from a retrospective cohort study including 16,462 women with BC who underwent surgery.

Disclosures: This study was funded by the Ministry of Health and Welfare, Republic of Korea. Some authors declared being members of a board of directors, stockholders of, or receiving grants from various sources.

Source: Cheun JH et al. Locoregional recurrence patterns in patients with different molecular subtypes of breast cancer. JAMA Surg. 2023 (Jun 21). Doi: 10.1001/jamasurg.2023.2150

Key clinical point: Pathologic regional lymph node stages I-III (pN1-3) and pathologic tumor size stage IV (pT4) were associated with worse long-term breast-cancer–specific survival (BCSS) outcomes in patients with human epidermal growth factor receptor 2-positive (HER2+) breast cancer (BC).

Major finding: In patients who were followed up for more than 60 months, increasing vs no nodal involvement (pN1-3 vs pN0; all hazard ratios [HR] >3; all P ≤ .001) and a tumor size of pT4 vs pT1 (HR 4.528; P = .007) were associated with poor BCSS outcomes.

Study details: This study used data from a registry to analyze 20,672 patients with HER2+ stage I-III BC who underwent surgery.

Disclosures: This study was supported by the Korean Breast Cancer Society. The authors declared no conflicts of interest.

Source: Kang YJ et al. Predictive biological factors for late survival in patients with HER2-positive breast cancer. Sci Rep. 2023;13:11008 (Jul 7). Doi: 10.1038/s41598-023-38200-y

Key clinical point: Pathologic regional lymph node stages I-III (pN1-3) and pathologic tumor size stage IV (pT4) were associated with worse long-term breast-cancer–specific survival (BCSS) outcomes in patients with human epidermal growth factor receptor 2-positive (HER2+) breast cancer (BC).

Major finding: In patients who were followed up for more than 60 months, increasing vs no nodal involvement (pN1-3 vs pN0; all hazard ratios [HR] >3; all P ≤ .001) and a tumor size of pT4 vs pT1 (HR 4.528; P = .007) were associated with poor BCSS outcomes.

Study details: This study used data from a registry to analyze 20,672 patients with HER2+ stage I-III BC who underwent surgery.

Disclosures: This study was supported by the Korean Breast Cancer Society. The authors declared no conflicts of interest.

Source: Kang YJ et al. Predictive biological factors for late survival in patients with HER2-positive breast cancer. Sci Rep. 2023;13:11008 (Jul 7). Doi: 10.1038/s41598-023-38200-y

Key clinical point: Pathologic regional lymph node stages I-III (pN1-3) and pathologic tumor size stage IV (pT4) were associated with worse long-term breast-cancer–specific survival (BCSS) outcomes in patients with human epidermal growth factor receptor 2-positive (HER2+) breast cancer (BC).

Major finding: In patients who were followed up for more than 60 months, increasing vs no nodal involvement (pN1-3 vs pN0; all hazard ratios [HR] >3; all P ≤ .001) and a tumor size of pT4 vs pT1 (HR 4.528; P = .007) were associated with poor BCSS outcomes.

Study details: This study used data from a registry to analyze 20,672 patients with HER2+ stage I-III BC who underwent surgery.

Disclosures: This study was supported by the Korean Breast Cancer Society. The authors declared no conflicts of interest.

Source: Kang YJ et al. Predictive biological factors for late survival in patients with HER2-positive breast cancer. Sci Rep. 2023;13:11008 (Jul 7). Doi: 10.1038/s41598-023-38200-y

Key clinical point:Although the cumulative incidence of myeloid neoplasms, such as myelodysplastic syndromes (MDS) and acute myeloid leukemias (AML), was low in breast cancer (BC) survivors, the receipt of anthracycline-based adjuvant therapy was associated with a long-term risk for both AML and MDS.

Major finding: The 10-year cumulative incidences of both AML and MDS were very low (~0.2%) in the anthracycline group and <0.2% in the chemotherapy without anthracycline and no chemotherapy groups. However, the risk for AML (hazard ratio [HR] 9.531;  95% CI 4.156-21.861) and MDS (HR 2.559;  95% CI 1.600-4.095) was significantly higher in the anthracycline group vs no chemotherapy group.

Study details: Findings are from a retrospective cohort study including 153,565 patients with BC who underwent surgery and received adjuvant treatment with anthracyclines (n = 79,321), chemotherapy without anthracyclines (n = 15,475), or no chemotherapy (n = 46,657).

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Lee JW et al. Therapy related myeloid neoplasm in early breast cancer patients treated with adjuvant chemotherapy. Eur J Cancer. 2023;191:112952 (Jun 22). Doi: 10.1016/j.ejca.2023.112952

Key clinical point:Although the cumulative incidence of myeloid neoplasms, such as myelodysplastic syndromes (MDS) and acute myeloid leukemias (AML), was low in breast cancer (BC) survivors, the receipt of anthracycline-based adjuvant therapy was associated with a long-term risk for both AML and MDS.

Major finding: The 10-year cumulative incidences of both AML and MDS were very low (~0.2%) in the anthracycline group and <0.2% in the chemotherapy without anthracycline and no chemotherapy groups. However, the risk for AML (hazard ratio [HR] 9.531;  95% CI 4.156-21.861) and MDS (HR 2.559;  95% CI 1.600-4.095) was significantly higher in the anthracycline group vs no chemotherapy group.

Study details: Findings are from a retrospective cohort study including 153,565 patients with BC who underwent surgery and received adjuvant treatment with anthracyclines (n = 79,321), chemotherapy without anthracyclines (n = 15,475), or no chemotherapy (n = 46,657).

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Lee JW et al. Therapy related myeloid neoplasm in early breast cancer patients treated with adjuvant chemotherapy. Eur J Cancer. 2023;191:112952 (Jun 22). Doi: 10.1016/j.ejca.2023.112952

Key clinical point:Although the cumulative incidence of myeloid neoplasms, such as myelodysplastic syndromes (MDS) and acute myeloid leukemias (AML), was low in breast cancer (BC) survivors, the receipt of anthracycline-based adjuvant therapy was associated with a long-term risk for both AML and MDS.

Major finding: The 10-year cumulative incidences of both AML and MDS were very low (~0.2%) in the anthracycline group and <0.2% in the chemotherapy without anthracycline and no chemotherapy groups. However, the risk for AML (hazard ratio [HR] 9.531;  95% CI 4.156-21.861) and MDS (HR 2.559;  95% CI 1.600-4.095) was significantly higher in the anthracycline group vs no chemotherapy group.

Study details: Findings are from a retrospective cohort study including 153,565 patients with BC who underwent surgery and received adjuvant treatment with anthracyclines (n = 79,321), chemotherapy without anthracyclines (n = 15,475), or no chemotherapy (n = 46,657).

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Lee JW et al. Therapy related myeloid neoplasm in early breast cancer patients treated with adjuvant chemotherapy. Eur J Cancer. 2023;191:112952 (Jun 22). Doi: 10.1016/j.ejca.2023.112952

Key clinical point: Patients with germline (g) BRCA1/2-associated primary breast cancer (BC), particularly those with gBRCA2 pathogenic mutations, faced a moderately increased risk of developing contralateral breast cancer (CBC) after receiving adjuvant radiotherapy.

Major finding: The risk for invasive and in situ CBC increased by 44% in patients with gBRCA1/2 mutations who did vs did not receive radiotherapy (adjusted hazard ratio [HR] 1.44;  95% CI 1.12-1.86), with the risk being even more prominent in gBRCA2 pathogenic variant carriers (adjusted HR 1.77;  95% CI 1.13-2.77).

Study details: Findings are from an analysis including 3602 patients with gBRCA1/2-associated primary BC from the prospective international BRCA1/2 Carrier Cohort Study, of whom 64% of patients received adjuvant radiotherapy.

Disclosures: This study did not receive any specific external funding. DG Evans reported ties with AstraZeneca and AmGen, K Kast declared ties with Roche Pharma AG, and J Simard declared holding patents related to BRCA1 and BRCA2.

Source: van Barele M et al. Contralateral breast cancer risk in irradiated breast cancer patients with a germline-BRCA1/2 pathogenic variant. J Natl Cancer Inst. 2023 (Jun 27). Doi: 10.1093/jnci/djad116

Key clinical point: Patients with germline (g) BRCA1/2-associated primary breast cancer (BC), particularly those with gBRCA2 pathogenic mutations, faced a moderately increased risk of developing contralateral breast cancer (CBC) after receiving adjuvant radiotherapy.

Major finding: The risk for invasive and in situ CBC increased by 44% in patients with gBRCA1/2 mutations who did vs did not receive radiotherapy (adjusted hazard ratio [HR] 1.44;  95% CI 1.12-1.86), with the risk being even more prominent in gBRCA2 pathogenic variant carriers (adjusted HR 1.77;  95% CI 1.13-2.77).

Study details: Findings are from an analysis including 3602 patients with gBRCA1/2-associated primary BC from the prospective international BRCA1/2 Carrier Cohort Study, of whom 64% of patients received adjuvant radiotherapy.

Disclosures: This study did not receive any specific external funding. DG Evans reported ties with AstraZeneca and AmGen, K Kast declared ties with Roche Pharma AG, and J Simard declared holding patents related to BRCA1 and BRCA2.

Source: van Barele M et al. Contralateral breast cancer risk in irradiated breast cancer patients with a germline-BRCA1/2 pathogenic variant. J Natl Cancer Inst. 2023 (Jun 27). Doi: 10.1093/jnci/djad116

Key clinical point: Patients with germline (g) BRCA1/2-associated primary breast cancer (BC), particularly those with gBRCA2 pathogenic mutations, faced a moderately increased risk of developing contralateral breast cancer (CBC) after receiving adjuvant radiotherapy.

Major finding: The risk for invasive and in situ CBC increased by 44% in patients with gBRCA1/2 mutations who did vs did not receive radiotherapy (adjusted hazard ratio [HR] 1.44;  95% CI 1.12-1.86), with the risk being even more prominent in gBRCA2 pathogenic variant carriers (adjusted HR 1.77;  95% CI 1.13-2.77).

Study details: Findings are from an analysis including 3602 patients with gBRCA1/2-associated primary BC from the prospective international BRCA1/2 Carrier Cohort Study, of whom 64% of patients received adjuvant radiotherapy.

Disclosures: This study did not receive any specific external funding. DG Evans reported ties with AstraZeneca and AmGen, K Kast declared ties with Roche Pharma AG, and J Simard declared holding patents related to BRCA1 and BRCA2.

Source: van Barele M et al. Contralateral breast cancer risk in irradiated breast cancer patients with a germline-BRCA1/2 pathogenic variant. J Natl Cancer Inst. 2023 (Jun 27). Doi: 10.1093/jnci/djad116